Without this barrier, asthma sufferers are far more likely to get long-term inflammation, wound healing, and infections that ...

Asthma is a chronic inflammatory disease that affects the lungs. In a child with asthma, the airways are very sensitive, ...

age of asthma onset, disease duration, atopy, gender, symptoms, medication use and health care usage. The existence of these distinct phenotypes suggests that several pathologic mechanisms promote ...

Airway inflammation has emerged as an important contributor to mechanisms of asthma. Furthermore, the presence of airway inflammation is present even in the absence of severe symptoms. To study ...

Can interventional strategies in the early prenatal period counteract any negative epigenetic changes that may predispose to asthma ... Identifying immunological mechanisms that explain these ...

Poorly controlled asthma during pregnancy can lead to serious complications, such as low birth weight, preterm delivery, and ...

Through our work, we found that mast cells likely protect against the mechanisms that drive severe ... which is common in ...

A Potential Therapeutic Target for Steroid Resistant Asthma,” published in the December 2024 issue of Allergy and Immunology by Berkinbayeva et al. Asthma is a chronic inflammatory disease, with a ...

The study, published in Science Translational Medicine on Jan. 15, 2025, sheds light on the complex mechanisms behind severe asthma and opens new avenues for potential treatments. Asthma is a ...

Further research is recommended regarding the effects of exercise on underlying pathophysiological mechanisms and asthma control in children with asthma. Children and exercise Training Physical ...

Equine asthma is a chronic inflammatory respiratory tract disease caused by an immunological reaction due to hypersensitivity. The pathogenetic mechanism of equine asthma is not fully known, which ...

Ethris announces promising phase 1 results for ETH47, its mRNA therapy for uncontrolled asthma. The inhaled treatment showed strong safety and efficacy, with plans for a phase 2 trial in 2025.